To date, less than 20 nanoformulations (liposome-based, albumin-bound, iron-based, etc.)have been approved by the Food and Drug Administration (FDA) or the European Medicines Agency (EMA) for the treatment of solid tumors, including breast cancer [141,142]. The gene discussed is ALB; the disease is breast cancer.